The Global Cluster Headache Market size is expected to reach $437.5 Million by 2028, rising at a market growth of 4.0% CAGR during the forecast period.
Cluster headaches are the most prevalent among the primary trigeminal autonomic cephalgia headache forms. These headaches might happen once every two days to eight times each day, just like other trigeminal autonomic cephalgias. These happen around the same time of day, most frequently at night. Most patients experience attacks daily for weeks to months, followed by remission lasting months to years. A cluster headache is a transient unilateral headache.
Depending on how long a cluster headache lasts, it might be classified as either episodic or chronic. Chronic cluster headache attacks last more than a year without remission or less than two weeks. Cluster headaches start suddenly and without any prior pain. On one side of the head, the pain is intense and frequently characterized as searing, burning, or piercing. It is frequently felt near the eye, temple, and occasionally the cheek.
During each strike, it often targets the same side. Because of how intense the pain is during an attack; people frequently feel restless and agitated and may respond by rocking or pacing their heads. Although the precise etiology of cluster headaches is unknown, they have been associated with activity in the hypothalamus, a brain region. Smokers appear to be more susceptible to developing cluster headaches.
There may be a hereditary relationship between cluster headaches and other family members for certain people who get them. A cluster headache episode may occasionally be brought on by consuming alcohol or inhaling strong odors like paint, perfume, or gasoline. During the symptom-free phase (remission), the headaches may go away for weeks, months, or even years before returning.
Headaches from COVID-19 are a sign of systemic viral infections and a headache does not aid the diagnosis or prognosis of COVID-19 infection. Headache is a symptom of COVID-19 infection, which frequently coexists with fever and may even be reliant upon it. Also, long COVID-19 headaches may manifest as a main headache that has already started to worsen or, more precisely, as a new (intermittent or daily) headache that begins during the acute infection or after a delay. Thus, a rising occurrence of headaches in pandemic-infected individuals is projected to drive market expansion.
the cluster headache patterns point to the hypothalamus, the body's circadian clock, as a potential contraibuting factor. Unlike migraine and tension headaches, cluster headache is typically not brought on by triggers such as certain meals, hormonal changes, or stress. Yet, consuming alcohol could swiftly create a splitting headache once a cluster phase starts. The usage of drugs like nitroglycerin, a prescription used to treat heart problems, is another potential cause. The growing prevalence of cluster headaches due to changing lifestyles and the consumption of some drugs or alcohol will propel the market growth.
Natural compounds and their structural analogs have significantly influenced pharmacology. Recent advancements in technology and science, including enhanced analytical tools, genome mining and engineering techniques, and improvements in microbial culture, are tackling existing issues and creating new possibilities. To combat antimicrobial resistance, this has revived interest in natural compounds as drug leads. The use of natural compounds and the increasing pharmaceutical-based R&D will enhance the effectiveness of the cluster headache medications, which will drive the market expansion.
Cluster headaches have no known permanent cure, and the other treatments are aimed at lessening pain intensity, minimizing the duration of the headache, and stopping episodes. Because they require quick-acting medications and their pain may arise suddenly and vanish swiftly, cluster headaches can be difficult to detect and treat. The exact etiology of cluster headaches is unknown. Cluster headaches are not subject to any tests. A doctor will often make a diagnosis by investigating a patient's symptoms and headache history and usually keep a headache journal with a list of symptoms that might be useful.
Based on drug class, the cluster headache market is segmented into ergot derivatives, calcium channel blockers, triptans and others. The triptans segment dominated the cluster headache market with the maximum revenue share in 2021. This is because they are a class, or group, of medicines that can stop migraine episodes. These drugs work to lessen symptoms by constricting enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present in several dose formulations. Depending on the symptoms, the doctor may recommend a different dose type, like the doctor could recommend a nasal spray rather than tablets to ingest if the patient is experiencing nausea and vomiting along with the migraine.
On the basis of distribution channel, the cluster headache market is divided into hospital pharmacies, drug stores & retail pharmacies and others. The drug stores & retail pharmacies segment held the highest revenue share in the cluster headache market in 2021. The growth is owing to a rise in consumer preference for retail pharmacies, which offer advice on drugs and their use throughout treatment periods. They offer first-rate customer service, affordable prices, and a large variety of general healthcare and home goods. Local pharmacists can also provide one-on-one consultations and guidance right away.
By type, the cluster headache market is classified into episodic and chronic. The chronic segment garnered a prominent revenue share in the cluster headache market in 2021. This is due to the fact that most people with cluster headaches suffer from the chronic kind. Chronic cluster headaches might develop from the episodic form over time, or they can be present from the start, which drives the segment's expansion. Like cluster headaches, chronic paroxysmal hemicrania (CPH) condition has shorter-lasting and more frequent symptoms, further expanding the segment growth.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 335.5 Million |
| Market size forecast in 2028 | USD 437.5 Million |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 4% from 2022 to 2028 |
| Number of Pages | 201 |
| Number of Table | 350 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Drug Class, Distribution channel, Type, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region-wise, the cluster headache market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the cluster headache market in 2021. This growth is owing to an increase in cluster headache instances in the region. In addition, there is an increase in major players offering innovative therapies and the presence of improved healthcare infrastructure. With a thriving sophisticated healthcare infrastructure, and the introduction of cutting-edge technology to detect illness, the market is anticipated to propel during the projected period.
Free Valuable Insights: Global Cluster Headache Market size to reach USD 437.5 Million by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
By Distribution channel
By Type
By Drug Class
By Geography
The global Cluster Headache Market size is expected to reach $437.5 Million by 2028.
Increase in cluster headache frequency are driving the market in coming years, however, Limited knowledge of the condition restraints the growth of the market.
Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
The Episodic segment acquired maximum revenue share in the Global Cluster Headache Market by Type in 2021 thereby, achieving a market value of $300.2 Million by 2028.
The North America market dominated the Global Cluster Headache Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $162 Million by 2028.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
